Analytical Data
-
Gene name
CLGN
- Application
-
Alternative Names
CLGN；Calmegin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P03956
-
Expression Region
20-469aa
-
AA Sequence
FPATLETQEQDVDLVQKYLEKYYNLKNDGRQVEKRRNSGPVVEKLKQMQE FFGLKVTGKPDAETLKVMKQPRCGVPDVAQFVLTEGNPRWEQTHLTYRIE NYTPDLPRADVDHAIEKAFQLWSNVTPLTFTKVSEGQADIMISFVRGDHR DNSPFDGPGGNLAHAFQPGPGIGGDAHFDEDERWTNNFREYNLHRVAAHE LGHSLGLSHSTDIGALMYPSYTFSGDVQLAQDDIDGIQAIYGRSQNPVQP IGPQTPKACDSKLTFDAITTIRGEVMFFKDRFYMRTNPFYPEVELNFISV FWPQLPNGLEAAYEFADRDEVRFFKGNKYWAVQGQNVLHGYPKDIYSSFG FPRTVKHIDAALSEENTGKTYFFVANKYWRYDEYKRSMDPGYPKMIAHDF PGIGHKVDAVFMKDGFFYFFHGTRQYKFDPKTKRILTLQKANSWFNCRKN HHHHHHHHHH
-
Molecular Weight
53 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLGN (Cell Lysis Gene N) is a significant protein in the context of cellular mechanisms and disease pathology, particularly in relation to its role in apoptosis and immune response. Research into CLGN has gained momentum due to its potential implications in various disorders, including cancer and autoimmune diseases. As an integral part of cellular homeostasis, CLGN is involved in regulating cell viability and can influence the efficacy of therapeutic strategies aimed at inducing cell death in malignant cells. Advances in recombinant protein technology have enabled scientists to produce CLGN in a more efficient manner, facilitating detailed studies into its structure, function, and interactions with other cellular proteins. Understanding the molecular dynamics of CLGN is crucial for deciphering its role in pathological conditions and exploring its potential as a biomarker or therapeutic target. With an emphasis on protein engineering and expression systems, current research seeks to elucidate the exact mechanisms by which CLGN participates in cellular lysis and immune modulation, paving the way for novel interventions that harness its natural functions for therapeutic benefit. The insights gained from recombinant CLGN studies are anticipated to contribute significantly to the fields of cancer biology and immunotherapy, underscoring the importance of this protein in both fundamental research and clinical applications.
